Montenegro - kroatia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"adoc" d.o.o. beograd predstavniŠtvo u podgorici - in vitro dijagnostička medicinska sredstva

Montenegro - kroatia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, posredovanje i promet "urion" d.o.o. podgorica - medicinska sredstva za jednokratnu upotrebu

Montenegro - kroatia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - vakcina protiv gripa (površinski antigeni, inaktivisana) - suspenzija za injekciju u napunjenom injekcionom špricu - 15mcg/0.5ml + 15mcg/0.5ml + 15mcg/0.5ml

Montenegro - kroatia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - vakcina protiv gripa (površinski antigeni, inaktivisana) - suspenzija za injekciju u napunjenom injekcionom špricu - 15mcg/0.5ml + 15mcg/0.5ml + 15mcg/0.5ml

Euroopan unioni - kroatia - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Bosnia ja Hertsegovina - kroatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 100 µg/1 doza - 1 doza praška inhalata, doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 100 µg flutikazonpropionata

Bosnia ja Hertsegovina - kroatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 250 µg/1 doza - 1 doza praška inhalata doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 250 µg flutikazonpropionata

Bosnia ja Hertsegovina - kroatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 500 µg/1 doza - 1 doza praška inhalata, doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 500 µg flutikazonpropionata

Euroopan unioni - kroatia - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - drugi gastrointestinalni trakt i metabolizam, lijekovi, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Euroopan unioni - kroatia - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.